Cure Rate After Chemotherapy in Stage III Ovarian Cancer
Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured.
Ovarian Cancer
Eligibility for First-Line PARP Inhibitor Maintenance in Advanced Ovarian Cancer
Many patients with advanced ovarian cancer may be eligible for first-line maintenance with a PARP inhibitor, research suggests.
Effect of HIPEC With Cytoreductive Surgery on HRQOL in Patients With Advanced Ovarian Cancer
A randomized study sought to determine the effect of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy on HRQOL for patients with advanced ovarian cancer.
Trabectedin No Better Than Physician’s Choice in Recurrent Ovarian Cancer
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Mirvetuximab Soravtansine Granted Priority Review for Ovarian Cancer
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
Olaparib Alone, in Combination Does Not Improve PFS in Platinum-Sensitive Ovarian Cancer
Despite the lack of improvement in the overall cohort, olaparib monotherapy and olaparib-cediranib did exhibit activity in a subset of patients with a germline BRCA mutation.
Multichannel Delivery System Optimal for Genetic Counseling in Ovarian Cancer
An interview study was conducted to determine preferences regarding information related to genetic counseling and testing among patients with ovarian cancer.
Attachment Insecurity and Depression, Anxiety in Ovarian Cancer Patient Partner-Caregivers
A cross-sectional study sought to determine how caregiving responsibilities affect mental health of partner-caregivers.
Avelumab Provides No Benefit as Frontline Therapy or Maintenance in Ovarian Cancer
Avelumab did not improve progression-free survival when given concurrently with chemotherapy or as maintenance.
Updated Data Confirm Safety of Olaparib Maintenance in Advanced Ovarian Cancer
Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.
- Loading...
Loading...
Next post in Ovarian Cancer
Loading... 
Loading...